Skip to main navigation Skip to search Skip to main content

A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination with Ivacaftor in Subjects 6 throught 11 years of Age with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Project: Research

Project Details

StatusFinished
Effective start/end date10/20/17 → 10/20/19

Funding

  • Vertex Pharmaceuticals Incorporated: $91,569.96